Compare Amer Sports Inc (AS) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amer Sports Inc vs Quest Diagnostics Inc — how do they compare? Amer Sports Inc trades at $33.87 (market cap $19.69B), while Quest Diagnostics Inc trades at $237.51 (market cap $26.21B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Amer Sports Inc pays none. Which is the better fit depends on your goals.
| AS | DGX | |
|---|---|---|
Market Cap | $19.69B | $26.21B |
Sector | Technology | Health |
52-Week High | $41.96 | $238.50 |
52-Week Low | $29.54 | $173.49 |
Enterprise Value | $20.01B | $31.97B |
Dividend Yield | — | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amer Sports (AS) trades at $33.03, down 8.68% in the past 24 hours, with a bearish technical signal from moving averages. The company reported strong Q1 2026 earnings of $0.38 per share, beating estimates, and raised full-year guidance. Revenue grew 32% year-over-year to $1.95 billion, driven by Arc'teryx and Salomon. Valuation ratios include a P/E of 42.3 and P/S of 2.8. Net income margin stands at 6.5% for 2025.
The outlook is positive due to consistent earnings beats and raised guidance, but high valuation and technical bearishness pose risks. Analyst consensus is strongly bullish with a $58.67 price target, suggesting significant upside. Key risks include reliance on brand momentum and market volatility. Investors should weigh strong fundamentals against current technical weakness.
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amer Sports Inc
Amer Sports is a global group of iconic sports and outdoor brands, including Arc'teryx, Salomon, Wilson, and Atomic. It designs and manufactures high-quality equipment, apparel, and footwear for athletes worldwide.
Read more on AS →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
